- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00327522
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
October 9, 2008 updated by: GlaxoSmithKline
An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.
The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is open and subjects will receive two vaccine doses of GSK Biologicals' 11 PCV vaccine.
Five blood samples will be taken: prior to and one month after each vaccine dose, and 2 weeks after dose 2.
Study Type
Interventional
Enrollment
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gent, Belgium, 9000
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy male or female between 18 and 40 years of age
- 23-valent pneumococcal polysaccharide vaccine naive adults.
Exclusion Criteria:
- Previous vaccination against Streptococcus pneumoniae.
- History of pneumonia within 3 years prior to the first vaccination
- Any confirmed or suspected immunosuppressive or immunodeficient condition
- All malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years.
- Subjects with documented anaemia or iron-deficiency (Hemoglobin level more than 10% below lower limit of normal)
- History of administration of an experimental/licensed vaccine containing similar adjuvants.
- History of chronic alcohol consumption and/or drug abuse.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Occurrence of solicited local & general symptoms (Day 0-7) and unsolicited symptoms (Day 0-30) after vaccination. Occurrence of serious adverse events during the entire study;
|
Frequencies of IgG PS-specific plasma cells (by B-cell ELISPOT) for 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) prior to & 1 month post dose 1, 2 weeks & 1 month post dose 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Study Registration Dates
First Submitted
May 17, 2006
First Submitted That Met QC Criteria
May 17, 2006
First Posted (Estimate)
May 18, 2006
Study Record Updates
Last Update Posted (Estimate)
October 13, 2008
Last Update Submitted That Met QC Criteria
October 9, 2008
Last Verified
October 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 106962
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prophylactic Pneumococcal Diseases
-
Innoblative Designs, Inc.University of ArkansasCompletedProphylactic Mastectomy
-
xunaNanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaboratorsWithdrawnProphylactic HQP1351 Therapy | Third Generation TKIChina
-
Intuitive SurgicalTerminatedProphylactic Nipple Sparing Mastectomy (NSM)Italy, France
-
Medical University of GrazKrankenhaus der Barmherzigen Bruder Graz; Krankenhaus der Elisabethinen Graz; Landeskrankenhaus Feldbach and other collaboratorsCompletedLaparoscopic Cholecystectomy | Prophylactic Salpingectomy | Opportunistic SalpingectomyAustria
-
Umeå UniversityRecruiting
-
University of OttawaNot yet recruitingPneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine AttitudeCanada
-
PfizerCompletedPneumococcal Vaccines | Pneumococcal Conjugate VaccineJapan
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, Pneumococcal | Vaccines, Pneumococcal Conjugate Vaccine
-
Stanford UniversityNot yet recruitingMastectomy | Nipple Sparing Mastectomy | Prophylactic Mastectomy | Gender Affirmation Surgery | Benign Breast ConditionUnited States
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumour | Malignant Haematological Tumour | Primary or Secondary Prophylactic TreatmentGermany
Clinical Trials on pneumococcal vaccine
-
GlaxoSmithKlineCompletedInfections, StreptococcalCzechia
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
SanofiCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedRespiratory Tract Infections | Respiratory Tract Diseases | PneumoniaChina
-
SanofiCompletedPneumoccocal ImmunisationUnited States
-
French National Agency for Research on AIDS and...Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland
-
Centers for Disease Control and PreventionSouthcentral Foundation; Alaska Native Tribal Health ConsortiumCompletedPneumococcal InfectionsUnited States
-
Helsinki University Central HospitalCompleted